Chris Garabedian (Forge Biologics)
Chris Garabedian's first Xontogeny company, Landos Biopharma, preps a nine-figure IPO as lead program heads to PhIII
Landos Biopharma, the lead company in the portfolio of Chris Garabedian’s fund with Perceptive, is preparing to go public about a year and a half …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
